On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.
Keynote Lecture: A role and rationale for neoadjuvant therapy in the melanoma treatment landscape & Session 1: Foundational Experience from Other Areas in Oncology
Session 2: Current Melanoma Neoadjuvant Experience
Session 3: Optimal Clinical Trial Design and Patient Selection
Panel Discussion with Audience Q&A — Working Together to Develop Neoadjuvant Therapies in Melanoma
This post was originally published by the Melanoma Research Alliance. It is republished with permission.